Accu-Chek missiOn: SMBG in Patients With diAbetes on inSulin Study (COMPASS) - Multiple Center, Open, and Non-randomized Study

Roche

Status: Completed

Conditions: Diabetes Mellitus Type 2

Treatments: Device: Accu-Chek Integra Glucometer

Study type: Interventional

Funder types: Industry

Identifiers

NCT01130480

RD000933

Details and patient eligibility

About

COMPASS is a status and intervention study for the self-monitoring of blood glucose (SMBG) in type 2 diabetic patients with insulin treatment. This multi-centre, open-label prospective study will assess the use and frequency of SMBG and blood glucose control and its influencing factors with the help of Accu-Chek Integra glucometer. Patients with type 2 diabetes mellitus who have received more than 3 months of insulin therapy are eligible to participate in this study. The anticipated duration of the study is 6 months.

Enrollment: 833 patients

Sex: All

Ages: Under 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Type II diabetes mellitus patients who have received insulin treatment for more than 3 months
• Patients willing to sign written informed consent form
• Patients who meet the criteria for the first cross-sectional investigation and have an HbA1c < 7% will receive the second cross-sectional investigation

Exclusion criteria

• Patients unable or unwilling to comply with the requirements of the protocol

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

833 participants in 1 patient group

A

Experimental group

Treatment:

Device: Accu-Chek Integra Glucometer